Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Paisan Ruamviboonsuk: saving sight in Thailand945
Vitamin D supplementation and mortality849
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY567
Madelung's disease in a rare 14th century Franco-Flemish woolen tapestry515
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial493
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality407
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study – Authors' reply399
South Africa to produce insulin for Africa in 2024388
Correction to Lancet Diabetes Endocrinol 2023; 11: 942–54364
Correction to Lancet Diabetes Endocrinol 2025; 13: 221–62359
Prediabetes: much more than just a risk factor356
Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study339
Protein-binding therapy: a new approach to lower cholesterol336
Management of thyroid nodules309
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial305
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer291
Ashley Grossman: finding a calling in neuroendocrinology260
Mark Atkinson: bringing two worlds together240
Vitamin D to prevent acute respiratory infections238
Fetal growth patterns as early markers of fetal programming234
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals191
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis188
People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action187
Type 1 diabetes screening: need for ethical, equity, and health systems perspective186
Implications of technology guidelines for low-income and middle-income countries181
Diabetes and the WHO Model List of Essential Medicines181
The human factor172
Dissection of type 2 diabetes: a genetic perspective172
Insulin for all: a hope yet to be realised163
May Ng: a lifetime commitment to children160
A framework for improving diabetes care in humanitarian emergencies152
Tackling childhood obesity in low-socioeconomic status communities: what is the next step?152
New metrics to support diabetes education and advocacy149
Data processing in the DMagic cluster randomised controlled trial148
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study129
Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis125
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study124
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records124
Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study123
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial121
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries121
Global diabetes incidence trends in young adults120
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p114
Association of age with gaps in diabetes-related care and hospitalisations from childhood to young adulthood in Quebec, Canada: a cohort study113
Semaglutide for obesity: four STEPs forward, but more to come112
The growing global burden of thyroid cancer overdiagnosis112
Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme111
Diabetes and the WHO Model List of Essential Medicines108
Big babies, small babies: metformin exposure in pregnancy107
Iodine deficiency in Europe: vigilance and action required104
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study101
Milestone achievement for global access to blood glucose meters and test strips100
Reducing sodium intake: step-by-step targets yield success95
Thought for food: a Cushing's syndrome enigma explained94
What's preventing us from curbing the obesity crisis?94
Newer antidiabetic agents: at what price will they be cost effective?93
The growing clinical effect of SGLT2 inhibitors90
Progress in diabetes prevention or epidemiology—or both, or neither?90
Mendelian randomisation and vitamin D: the importance of model assumptions90
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era87
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes – Authors' reply85
Banning diabetes blanket bans82
Anand Hardikar: a scientific nomad searching for the truth82
Hot topics on insulin access: the issue of thermostability82
Gender disparities in publishing: from words to actions82
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale82
The food system: hunger for change81
The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial78
The relevance of T3 in the management of hypothyroidism78
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?78
What's in a decade?77
Call for prospective studies of continuous glucose monitoring to define the glycaemic response to bariatric surgery74
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs74
A compass for navigating the perils of hypertriglyceridaemia73
0.095631122589111